Abstract
This nonrandomized controlled trial examines the safety of radiation therapy (RT) followed by intrathecal trastuzumab and pertuzumab for patients with ERBB2-positive breast leptomeningeal disease (LMD).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have